Dr. Hamburg, but in the second paragraph of your letter last December, you talked about, 'Importing non-FDA-approved drugs represents four potential risks.' No one is talking about importing non-FDA-approved drugs.
Dorgan clarifies that the discussion is about FDA-approved drugs, not non-approved ones.
Share
More from Byron Dorgan
Although histories, cultures, and languages may be diverse, one theme was always consistent--the challenges of accessing healthcare and life-saving services.
I just want to say that I am concerned about the court's decision in Carcieri and the impact it may have on those tribes that were recognized after 1934.
Other voices in this conversation
